This site is intended for healthcare professionals residing in Canada.

Visit Pfizer AcademySearch

Menu

Close

Sign InLog Out
  • EN
ProductsTherapy AreasExplore ContentExplore
ContentGo to Explore ContentEventsMaterialsVideosPatient SupportContact
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Français

Menu

Close

Home

Recommendations

SOGC Recommendations

NACI Recommendations

CIQ Recommendations

About RSV

About RSV

Infants at Risk

Individuals ≥ 60 Years of Age

About ABRYSVO

Reconstitution and Storage

Dosing and Administration

Mechanism of Action

Efficacy and Safety Profiles

Clinical Trials

MATISSE Study Design

MATISSE Data

MATISSE Safety Profile

RENOIR Study Design

RENOIR Data

RENOIR Safety Profile

More

Coverage Information

Patient Profiles

FAQ

Resources

Product MonographSafety Information
Pfizer Respiratory Vaccine Portfolio
Consider which patients may be appropriate for ABRYSVO

James

Mohammed

Emily

Fatima

Meet James*“Now that I’m retired, I’m going to spend time with my wife and elderly parents.”
  • Age: 60
  • Comorbidities: COPD
  • Private insurance coverage
  • Has routine check-ups
TitleConsider recommending ABRYSVO during James’s check-up.COPD: chronic obstructive pulmonary disease; SOGC: Society of Obstetricians and Gynaecologists of Canada; NACI: National Advisory Committee on Immunization; CIQ: Comité sur l’immunisation du Québec
*Fictitious patient case. May not be representative of the general population.COPD: chronic obstructive pulmonary disease; SOGC: Society of Obstetricians and Gynaecologists of Canada; NACI: National Advisory Committee on Immunization; CIQ: Comité sur l’immunisation du Québec
*Fictitious patient case. May not be representative of the general population.
Meet Mohammed*“I recently moved into a retirement home. We’re going to celebrate my grandson’s birthday here; it will be nice to have the family around.”
  • Age: 73
  • Comorbidities: chronic kidney disease
  • Has access to public funding
  • Has routine check-ups with nursing staff
TitleConsider recommending ABRYSVO during Mohammed’s seasonal immunization schedule.SOGC: Society of Obstetricians and Gynaecologists of Canada; NACI: National Advisory Committee on Immunization; CIQ: Comité sur l'immunisation du Québec
*Fictitious patient case. May not be representative of the general population.SOGC: Society of Obstetricians and Gynaecologists of Canada; NACI: National Advisory Committee on Immunization; CIQ: Comité sur l'immunisation du Québec
*Fictitious patient case. May not be representative of the general population.
Meet Emily*“This is my first pregnancy.”
  • Age: 37
  • 35 weeks pregnant 
  • Private insurance coverage
  • Has had frequent check-ups and emergency visits
TitleConsider recommending ABRYSVO during Emily’s check-up.SOGC: Society of Obstetricians and Gynaecologists of Canada; NACI: National Advisory Committee on Immunization; CIQ: Comité sur l'immunisation du Québec
*Fictitious patient case. May not be representative of the general population.SOGC: Society of Obstetricians and Gynaecologists of Canada; NACI: National Advisory Committee on Immunization; CIQ: Comité sur l'immunisation du Québec
*Fictitious patient case. May not be representative of the general population.
Meet Fatima*“My doctor has been discussing vaccines I should take during my pregnancy. ABRYSVO is now an option for me.”
  • Age:31
  • 32 weeks pregnant
  • No comorbidities
  • Private insurance coverage
  • Has check-ups with her gynecologist
TitleConsider recommending ABRYSVO while Fatima is going for her vaccinations.COPD: chronic obstructive pulmonary disease; SOGC: Society of Obstetricians and Gynaecologists of Canada; NACI: National Advisory Committee on Immunization; CIQ: Comité sur l'immunisation du Québec
*Fictitious patient case. May not be representative of the general population.COPD: chronic obstructive pulmonary disease; SOGC: Society of Obstetricians and Gynaecologists of Canada; NACI: National Advisory Committee on Immunization; CIQ: Comité sur l'immunisation du Québec
*Fictitious patient case. May not be representative of the general population.
MoreEfficacy and Safety Profiles

Investigate ABRYSVO’s efficacy and safety profiles in infants and individuals ≥ 60 years of age.

Recommendations

Learn more about SOGC, NACI, and CIQ recommendations.

PP-A1G-CAN-0117-EN

To report an adverse event, please call 1-866-723-7111

PfizerPro AccountPfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign in or RegisterSign inRegisterAccountSign Out

© Pfizer Canada ULC 2024. All rights reserved. The information is intended only for healthcare professionals resident in Canada. ®Pfizer Inc., used under license.

PP-UNP-CAN-0145-EN
You are now leaving Pfizerpro.ca website
Links to other sites are provided as a convenience to the viewer, and should not be taken as an endorsement of the sites or an association with their owners. Pfizer Canada accepts no responsibility for the content of linked sites.
You are now leaving the PfizerPro Portal.
You are about to view resources made available by Pfizer Academy. 
These resources include learning programs and upcoming events. By selecting Go to link below, you acknowledge and certify that you are a Canadian Healthcare Professional.
PP-UNP-CAN-0013 EN
Are you a resident of Quebec?